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Background: The recently published cardiovascular outcomes data for the first sodium–glu-
cose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and 
additional benefits in patients with type 2 diabetes and established cardiovascular disease. 
Empagliflozin showed lower rates of death from cardiovascular causes or from any causes 
and lower hospitalization rates from heart failure compared with placebo, both in addition to 
standard care. This commentary discusses the existence of a possible class effect considering 
the available evidence described for other SGLT2 inhibitors.
Main text: Empagliflozin, dapagliflozin and canagliflozin share the same mechanism of action, 
and it is a plausible hypothesis that some of the benefits of empagliflozin treatment could also 
be expected from other SGLT2 inhibitors. However, the rapid and persistent occurrence of 
cardiovascular benefits observed with empagliflozin and the different results shown by the 
three inhibitors in meta-analyses of some of their respective Phase II and III trials might sug-
gest another possible mechanism of action, perhaps related to the different selectivity to inhibit 
SGLT-2 and other SGLT family members that these compounds present.
Conclusion: There is still lack of evidence to answer whether the cardiovascular benefits 
observed with empagliflozin in the EMPA-REG OUTCOME study could be seen as a “class 
effect”, which is also attributable to dapagliflozin and canagliflozin.
Keywords: cardiovascular, outcome studies, SGLT2 inhibitors, empagliflozin, dapagliflozin, 
canagliflozin
Background
Following presentation and publication of the results of the EMPA-REG OUTCOME 
study,1 which showed significantly lower rates of death from cardiovascular causes, death 
from any cause and hospitalization for heart failure with empagliflozin in patients with 
type 2 diabetes and established cardiovascular disease compared with placebo, both in 
addition to standard care, the question we must ask ourselves is whether the observed 
benefits could also be extended to other molecules in the same class of sodium–glucose 
cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin or canagliflozin.
Main text
It is true that all three drugs share the same mechanism of action. They all reduce 
hyperglycemia by decreasing renal reabsorption of glucose and inducing an increase 
in glycosuria. Increased urinary excretion of glucose is associated with weight loss 
due to loss of glucose (for every gram excreted, 4 kcal is lost) and a slight increase in 
diuresis.2 As regard the cardiovascular benefits observed with empagliflozin, it has been 
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suggested that they result from multidimensional changes that 
are directly or indirectly related to the induced glycosuria, 
such as weight loss and lower blood pressure, from visceral 
adiposity, hyperinsulinemia, albuminuria and elevated levels 
of uric acid. These actions have also been observed with 
dapagliflozin and canagliflozin and could mean that it is a 
plausible hypothesis that the benefits of empagliflozin could 
also be expected from other SGLT2 inhibitors (a class effect).3
However, the rapid and persistent occurrence of cardiovas-
cular benefits observed with empagliflozin indicates that it is 
probably not directly related to its antihyperglycemic, antihy-
pertensive, or weight loss effects (class effect) or an effect on 
atherosclerosis. This leads us to consider other possible mecha-
nisms of action (hemodynamic benefits, reduction in sympa-
thetic tone, antialdosterone effect, reduction in oxidative stress, 
reduction in myocardial oxygen demand, etc.), which may or 
may not be intrinsic to empagliflozin. There are also differences 
between the three molecules in terms of their selectivity toward 
the glucose transporter SGLT2, although the associated clini-
cal implications are unknown. Empagliflozin presents greater 
selectivity for SGLT2 versus SGLT1 (>2500-fold), followed 
by dapagliflozin (>1200-fold) and canagliflozin (>250-fold). 
Moreover, compared with SGLT6, both empagliflozin and 
dapagliflozin also showed more than 500-fold selectivity, 
whereas canagliflozin showed only 90-fold selectivity.4
What is more important, meta-analyses based on Phase 
II and III studies with empagliflozin, dapagliflozin and cana-
gliflozin show very different results.5–7 In all of them, the pri-
mary composite outcome was observation time required until 
the occurrence of death from cardiovascular causes, non-fatal 
myocardial infarction, non-fatal stroke or hospitalization for 
unstable angina. In the case of empagliflozin, the hazard ratio 
(HR) versus placebo was 0.48 (95% confidence interval [CI]: 
0.27–0.85), which indicates a cardiovascular risk reduction 
of -52%.5 Comparatively, the HR with dapagliflozin was 0.82 
(95% CI: 0.58–1.15; -18%)6 and with canagliflozin was 0.91 
(95% CI: 0.68–1.22; -9%).7 These data suggest, although 
only preliminarily, that there is a greater reduction in cardio-
vascular risk with empagliflozin than with dapagliflozin or 
canagliflozin, although it must be interpreted with caution, 
as mentioned earlier.
As regard prospective studies of the long-term cardiovas-
cular safety of SGLT2 inhibitors, we are awaiting the results 
of the CANagliflozin cardioVascular Assessment Study 
(CANVAS)8 with canagliflozin in 2017 and the Dapagliflozin 
Effect on CardiovascuLAR Events (DECLARE-TIMI 58) 
study with dapagliflozin in 2019. One important differ-
ence between the EMPA-REG OUTCOME study and these 
ongoing studies is the study populations (Table 1). Whereas 
the patients included in the EMPA-REG OUTCOME study 
had established vascular disease, in the CANVAS and 
DECLARE-TIMI 58 studies, the patients may have estab-
lished vascular disease or high cardiovascular risk.3 It is not 
known whether these differences could play an important part 
in demonstrating the cardiovascular benefits of the different 
drugs and in the magnitude of the effect.
If we review other therapeutic classes, highly differing 
results have also been found in cardiovascular safety stud-
ies between several of the drugs investigated. In the case of 
glitazones, rosiglitazone was withdrawn by the European 
Medicines Agency (EMA) due to aspects of cardiovascular 
safety suggested by a meta-analysis,9 while pioglitazone 
Table 1 Cardiovascular safety studies with empagliflozin, dapagliflozin and canagliflozin in patients with type 2 diabetes mellitus
Parameter EMPA-REG OUTCOME1 DECLARE-TIMI 5814 CANVAS8,15 CANVAS-R16
Drug Empagliflozin Dapagliflozin Canagliflozin Canagliflozin
n 7020 17276 4327 5826
Primary end point CV death, non-fatal MI or 
non-fatal stroke
CV death, non-fatal MI or 
ischemic stroke
CV death, non-fatal MI or 
non-fatal stroke
Progression of albuminuria
Main inclusion criteria Established CV disease, HbA1c 
≥7.0% and <9% (patients without 
previous hypoglycemic treatment) 
or <10% (patients with previous 
hypoglycemic treatment)
High risk for CV disease CV disease or high CV risk, 
HbA1c ≥7.0% and ≤10.5%
CV disease or high CV risk, 
HbA1c ≥7.0% and ≤10.5%
Study population
Age (years) 63.1 62.4
HbA1c (%) 8.1 8.2
CV disease (%) 99.4 62.7
End of study April 2015 April 2019 April 2017 January 2017
Note: Data from the CANVAS study are combined with data from the CANVAS-R study for a pre-specified cardiovascular safety meta-analysis.
Abbreviations: CV, cardiovascular; MI, myocardial infarction; HbA1c, glycated hemoglobin.
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showed benefits in the Prospective Pioglitazone Clinical Trial 
in Macrovascular Events (PROactive) study versus placebo, 
particularly in the main secondary end point, which consisted 
of the composite of all-cause mortality, non-fatal myocar-
dial infarction and stroke (HR 0.84, 95% CI: 0.72–0.98, 
p = 0.027).10 Likewise, in recently published studies with 
dipeptidyl peptidase 4 inhibitors, differences in cardiovascu-
lar aspects were also observed. In the Saxagliptin Assessment 
of Vascular Outcomes Recorded in Patients with Diabetes 
Mellitus (SAVOR-TIMI 53) trial, an increase was observed 
in the hospitalization rate for heart failure in patients treated 
with saxagliptin versus placebo (3.5% versus 2.8%; HR 1.27; 
95% CI: 1.07, 1.51; p = 0.007).11 However, these findings have 
not been observed in other cardiovascular safety studies with 
sitagliptin (Trial to Evaluate Cardiovascular Outcomes after 
Treatment with Sitagliptin [TECOS])12 or with alogliptin 
(EXamination of cArdiovascular outcoMes with alogliptIN 
versus standard of carE [EXAMINE]).13
Conclusion
The answer to the question as to whether the cardiovascular 
benefits observed with empagliflozin in the EMPA-REG 
OUTCOME study could be seen as a “class effect” will have 
to wait. So far, only empagliflozin has robustly demonstrated 
cardiovascular benefits in a specifically designed safety study 
following US Food and Drug Administration recommendations. 
Therefore, from a scientific point of view, it is advisable to await 
the publication of the results of currently ongoing specific car-
diovascular safety studies with dapagliflozin and canagliflozin 
before jumping to conclusions. Furthermore, these results must 
not be generalized to diabetic patients with a shorter time since 
diagnosis and without previous cardiovascular disease or to 
patients with cardiovascular disease but without diabetes.
Acknowledgments
We thank BCNscience, S.L. for their assistance with medical 
writing. This study was funded by Boehringer Ingelheim and 
Eli Lilly and Company. Boehringer Ingelheim and Eli Lilly 
companies were involved in manuscript preparation and 
publication decisions. 
Data supporting this commentary were obtained from 
cited articles. No primary or secondary dataset was created 
or used in this article.
Author contributions
All authors have made substantial contributions to concep-
tion, design and drafting of the manuscript or revising it 
critically for important intellectual content.
Disclosure
Doctor Francisco Javier Ampudia-Blasco and Doctor 
Ramón Gomis have carried out consulting work and/or 
conferences for Boehringer-Ingelheim and Lilly. Doctor 
Bernat Ariño is a full-time employee of Boehringer-
Ingelheim. Doctor Irene Romera is a full-time employee 
of Lilly Spain. The authors report no other conflicts of 
interest in this work.
References
 1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovas-
cular outcomes, and mortality in type 2 diabetes. N Engl J Med. 
2015;373(22):2117–2128.
 2. Scheen AJ. Evaluating SGLT2 inhibitors for type 2 diabetes: pharma-
cokinetic and toxicological considerations. Expert Opin Drug Metab 
Toxicol. 2014;10(5):647–663.
 3. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and car-
diovascular risk: proposed pathways and review of ongoing outcome 
trials. Diab Vasc Dis Res. 2015;12(2):90–100.
 4. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selec-
tive sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation 
and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 
2012;14(1):83–90.
 5. EMA. Jardiance EPAR: Public Assessment Report. 2016. Available 
from: http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Public_assessment_report/human/002677/WC500168594.
pdf. Accessed March 17, 2016.
 6. EMA. Ficha técnica Forxiga. 2016. Available from: http://www.ema.
europa.eu/docs/es_ES/document_library/EPAR_-_Product_Informa-
tion/human/002322/WC500136026.pdf. Accessed March 17, 2016.
 7. EMA. Ficha técnica Invokana. 2016. Available from: http://www.
ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_
Information/human/002649/WC500156456.pdf. Accessed March 
17, 2016.
 8. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline 
characteristics of the Canagliflozin Cardiovascular Assessment Study 
(CANVAS) – a randomized placebo-controlled trial. Am Heart J. 
2013;166(2):217–223e211.
 9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocar-
dial infarction and death from cardiovascular causes. N Engl J Med. 
2007;356(24):2457–2471.
10. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary pre-
vention of macrovascular events in patients with type 2 diabetes 
in the PROactive Study (PROspective pioglitAzone Clinical Trial 
In macroVascular Events): a randomised controlled trial. Lancet. 
2005;366(9493):1279–1289.
11. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovas-
cular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 
2013;369(14):1317–1326.
12. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin 
on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 
2015;373(3):232–242.
13. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute 
coronary syndrome in patients with type 2 diabetes. N Engl J Med. 
2013;369(14):1327–1335.
14. AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadas-
sah Medical Organization. Multicenter trial to evaluate the effect of 
dapagliflozin on the incidence of cardiovascular events (DECLARE-
TIMI58). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National 
Library of Medicine (US); 2000 [cited 2016 Mar 2017]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT01730534?term=declare+timi+
58&rank=1. NLM identifier: NCT01730534. Accessed November 7, 
2016.
International Journal of General Medicine 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
International Journal of General Medicine
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/international-journal-of-general-medicine-journal
The International Journal of General Medicine is an international, 
peer-reviewed open-access journal that focuses on general and internal 
medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-
ment protocols. The journal is characterized by the rapid reporting of 
reviews, original research and clinical studies across all disease areas. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Dovepress
26
Ampudia-Blasco et al
15. Janssen Research & Development; The George Institute for Global 
Health (Australia). CANVAS – CANagliflozin cardioVascular 
Assessment Study (CANVAS). In: ClinicalTrials.gov [Internet]. 
Bethesda, MD: National Library of Medicine (US); 2000. [cited 
2016 Mar 17]. Available from: https://clinicaltrials.gov/ct2/show/
NCT01032629?term=canvas&rank=1. NLM identifier: NCT01032629. 
Accessed November 7, 2016.
16. Janssen Research & Development; The George Institute for Global 
Health (Australia). A study of the effects of canagliflozin (JNJ-28431754) 
on renal endpoints in adult participants with type 2 diabetes mellitus 
(CANVAS-R). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National 
Library of Medicine (US). 2000 [cited 2016 17 Mar]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT01989754?term=canvas&rank=5. 
NLM identifier: NCT01989754. Accessed November 7, 2016.
